Maria del Pilar Leoz Allegretti

Ms. Maria del Pilar Leoz Allegretti


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMelina Mara Musri
Melina Mara Musri
VVVeronica Venturi
Veronica Venturi
XFXènia Ferrer-Cortès
Xènia Ferrer-Cortès
LRLídia Romero-Cortadellas
Lídia Romero-Cortadellas
GVGonzalo Hernandez Viedma
Gonzalo Hernandez Viedma
MSMayka Sanchez
Mayka Sanchez
Congenital dyserythropoietic anemia type II (CDA II) is an inherited autosomal recessive blood disorder which belongs to the wide group of ineffective erythropoiesis conditions. It is characterized by mild to severe normocytic anemia, jaundice, and splenomegaly owing to the hemolytic component. This often leads to liver iron overload and gallstones. CDA II is caused by biallelic mutations in the SEC23B gene. In this study, we report 9 new CDA II cases and identify 16 pathogenic variants, 6 of which are novel. The newly reported variants in SEC23B include three missenses (p.Thr445Arg, p.Tyr579Cys, and p.Arg701His), one frameshift (p.Asp693GlyfsTer2), and two splicing variants (c.1512-2A>G, and the complex intronic variant c.1512-3delinsTT linked to c.1512-16_1512-7delACTCTGGAAT in the same allele). Computational analyses of the missense variants indicated a loss of key residue interactions within the beta sheet and the helical and gelsolin domains, respectively. Analysis of SEC23B protein levels done in patient-derived lymphoblastoid cell lines (LCLs) showed a significant decrease in SEC23B protein expression, in the absence of SEC23A compensation. Reduced SEC23B mRNA expression was only detected in two probands carrying nonsense and frameshift variants; the remaining patients showed either higher gene expression levels or no expression changes at all. The skipping of exons 13 and 14 in the newly reported complex variant c.1512-3delinsTT/c.1512-16_1512-7delACTCTGGAAT results in a shorter protein isoform, as assessed by RT-PCR followed by Sanger sequencing. In this work, we summarize a comprehensive spectrum of SEC23B variants, describe nine new CDA II cases accounting for six previously unreported variants, and discuss innovative therapeutic approaches for CDA II.

4 September 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
SMSergio Matarraz
Sergio Matarraz
MAMaria del Pilar Leoz Allegretti
Maria del Pilar Leoz Allegretti
AYAna Yeguas-Bermejo
Ana Yeguas-Bermejo
VVVincent Van der Velden
Vincent Van der Velden
ABAnne E. Bras
Anne E. Bras
AOAlberto Orfao
Alberto Orfao

Verified
Journal Article
Open access
PDF file
JAJosé Manuel González De Aledo-Castillo
José Manuel González De Aledo-Castillo
AAAna Argudo-Ramírez
Ana Argudo-Ramírez
DBDavid Beneitez-Pastor
David Beneitez-Pastor
AGAnna Collado Gimbert
Anna Collado Gimbert
FCFrancisco Almazán Castro
Francisco Almazán Castro
OCon behalf of the Sickle Cell Disease Newborn Screening Group of Catalonia
on behalf of the Sickle Cell Disease Newborn Screening Group of Catalonia
In 2015, Catalonia introduced sickle cell disease (SCD) screening in its newborn screening (NBS) program along with standard-of-care treatments like penicillin, hydroxyurea, and anti-pneumococcal vaccination. Few studies have assessed the clinical impact of introducing NBS programs on SCD patients. We analyzed the incidence of SCD and related hemoglobinopathies in Catalonia and the change in clinical events occurring after introducing NBS. Screening 506,996 newborns from 2015 to 2022, we conducted a retrospective multicenter study including 100 screened (SG) and 95 unscreened (UG) SCD patients and analyzed SCD-related clinical events over the first six years of life. We diagnosed 160 cases of SCD, with an incidence of 1 in 3169 newborns. The SG had a significantly lower median age at diagnosis (0.1 y vs. 1.68 y, p < 0.0001), and initiated penicillin prophylaxis (0.12 y vs. 1.86 y, p < 0.0001) and hydroxyurea treatment earlier (1.42 y vs. 4.5 y, p < 0.0001). The SG experienced fewer median SCD-related clinical events (vaso-occlusive crisis, acute chest syndrome, infections of probable bacterial origin, acute anemia requiring transfusion, acute splenic sequestration, and pathological transcranial Doppler echography) per year of follow-up (0.19 vs. 0.77, p < 0.0001), a reduced number of annual emergency department visits (0.37 vs. 0.76, p < 0.0001), and fewer hospitalizations (0.33 vs. 0.72, p < 0.0001). SCD screening in Catalonia’s NBS program has effectively reduced morbidity and improved affected children’s quality of life.

13 November 2019 in Blood
Verified
Journal Article
Open access
SMSergio Matarraz
Sergio Matarraz
MAMaria del Pilar Leoz Allegretti
Maria del Pilar Leoz Allegretti
Xavier CalvoXavier Calvo
Xavier Calvo
LALuis García Alonso
Luis García Alonso
RBRosa Ayala Bueno
Rosa Ayala Bueno
AOAlberto Orfao
Alberto Orfao
Introduction. Nucleophosmin gene mutation (NPM1mut) occurs in around 30% of acute myeloid leukemia (AML) patients, frequently linked with favourable prognosis in the absence of FLT3-ITDmut, which occurs in around 40% of NPM1mutAML. Therefore, more expeditious diagnostic approaches may contribute to early diagnosis and prognostic stratification of these patients. Herein, we investigated the association of immunophenotypic features of leukemic and monocytic cells with the presence of NPM1mut in AML. Methods. A total of 404 bone marrow (BM) samples from newly-diagnosed AML patients according to WHO 2017 classification were retrospectively studied by 8-color flow cytometry, including 225 AML with NPM1mut and 179 cases wild type gene (NPM1wt). Information on FLT3-ITD could be obtained from 397/404 cases. Thus, FLT3-ITDmut was present in 85/397 (21%), being concomitant with NPM1mutin 62/85 AML cases (73%). Logistic regression analysis was used to identify predictive phenotypes for the presence of NPM1mut. Results. Overall, blast cell with immunophenotypic features of monocytic differentiation (corresponding to FAB M4 and M5 AML subtypes) were observed among 135/225 (60%) and 69/179 (38.5%) AML patients with NPM1mutand NPM1wt, respectively (p<0.001). In the remaining AML cases without monocytic differentiation (FAB M0, M1 and M2; n=200), both immature/myeloid blasts and remaining monocytic cells were immunophenotypically characterized. Among AML with monocytic blast cell differentiation, altered monocytic phenotypes were more frequent among NPM1mut vs. NPM1wtcases (98% vs. 36%) (p<0.001). In detail, these phenotypic alterations consisted of asynchronous expression of CD300e prior CD14 (79% vs. 5% NPM1wtcases, respectively; p<0.001) and/or CD35 prior CD14 (84% vs. 30%), which were observed independently of FLT3-ITD. Of note, coexistence of the latter two asynchronous monocytic patterns (CD300e prior CD14 and CD35 prior CD14) on monocytic blast cells was specific for NPM1mut (64% vs. 0% NPM1wtpatients; p<0.001). Noteworthy, in AML cases without blast cell monocytic differentiation, remaining monocytic cells showed similar asynchronous phenotypic patterns, which were also more frequent among NPM1mut cases (78% vs. 23% of NPM1wtcases, respectively; p <0.001). Thus, remaining monocytic cells from NPM1mut AML cases also showed a higher frequency of asynchronous CD300e prior CD14 (64% vs. 8% of NPM1wt cases; p<0.001) and CD35 prior CD14 expression (58% vs. 20% of NPM1wt cases, respectively; p<0.001). In addition, aberrant CD9 blast cell expression was found in a significant proportion of all AML cases studied (124/222, 56%). However, altered CD9 was more frequent on (either monocytic or immature/myeloid) blast cells from AML cases with NPM1mut (76% vs. 46% NPM1wtcases; p0.05). In turn, aberrant CD25 expression on blast cells was otherwise linked to FLT3-ITDmut (61% vs. 20% of FLT3-ITDwtcases; p<0.001), being more frequent in AML with FLT3-ITDmutNPM1wt and double mutated AML cases vs. AML with FLT3-ITDwtNPM1mut and FLT3-ITDwtNPM1wt (79% and 47% vs. 20% and 20% of cases, respectively; p<0.001). In addition, overall, FLT3-ITDmut was associated with a significantly higher proportion of immature (i.e. CD34+) blasts, as compared to FLT3-ITDwt cases (median of 10% vs. 0.3% CD34+ blasts; p<0.001). In multivariate analysis, baseline detection of monocytic-lineage blast cells with asynchronous expression of CD300 prior CD14 -C-index= 0.954, odds ratio (OR), 78.8; 95% confidence interval (CI), 13.1-471; p<0.001- and CD35 prior CD14 (OR, 24.5; 95% CI, 4.8-123; p<0.001) and detection of these asynchronous patterns on remaining monocytic cells from AML without monocytic differentiation (C-index= 0.816, OR, 14.7; 95% CI, 6.4-34; p<0.001 and, OR, 2.5; 95% CI, 1.2-5.3; p=0.01, respectively) showed the highest predictive value for NPM1mut in AML. In turn, CD25 aberrant blast cell expression was the only immunophenotypic parameter with predictive value for FLT3-ITDmut (OR, 6.4; 95% CI, 2.9-14.5; p<0.001). Conclusions. Detection of specific aberrant immunophenotypic patterns among blast cells and/or remaining monocytic cells from AML patients is highly predictive for NPM1mut, which may contribute to early diagnosis and follow-up of these patients. Disclosures: Díez-Campelo: Celgene Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

23 June 2026 in Blood
Verified
Journal Article
Closed access
ARAlba Rubio-Gayarre
Alba Rubio-Gayarre
MVMeritxell Vinyoles
Meritxell Vinyoles
JTJuan Ramón Tejedor
Juan Ramón Tejedor
MGMercedes Guerrero-Murillo
Mercedes Guerrero-Murillo
NFNarcís Fernandez-Fuentes
Narcís Fernandez-Fuentes
BLBelén Lopez-Millan
Belén Lopez-Millan
KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-r B-ALL) is an aggressive subtype of leukemia, characterized by high relapse rates, therapy resistance, and poor prognosis. Although CD19-targeted immunotherapies have significantly benefited patients with relapsed/refractory (R/R) disease, relapses remain common and long-term survival is especially poor in KMT2A-r B-ALL patients. We recently identified the membrane-bound proteoglycan NG2 (CSPG4) as direct transcriptional target of KMT2A fusions, with its expression associated with poor prognosis, early relapse, and glucocorticoid resistance in KMT2A-r B-ALL. However, the molecular mechanism underlying the aggressiveness of KMT2A-r B-ALL remains poorly understood. Here, we identify the α4 integrin subunit (ITGA4) and NG2 as a key biological axis contributing to leukemic aggressiveness. NG2 expression promotes proliferation and migration of KMT2A-r B-ALL cells and it is associated with Rho GTPase activity in an ITGA4-dependent manner. In vivo studies using immunodeficient mice demonstrated that ITGA4 and NG2 cooperate to promote leukemia progression as combined genetic ablation of both genes significantly delayed disease onset and prolonged survival. Notably, Natalizumab (NTZ) - an FDA/EMA-approved monoclonal antibody targeting ITGA4 - delayed leukemia progression and potentiated the efficacy of standard-of-care chemotherapy in KMT2A-r B-ALL patient-derived xenograft (PDX) models. Collectively, our findings define a novel ITGA4-NG2 signaling axis that drives the aggressiveness of KMT2A-r B-ALL and support the repurpose of NTZ as an adjuvant therapeutic strategy for this high-risk leukemia subtype.

2 November 2026 in European Journal of Haematology
Verified
Journal Article
Open access
GRGuillermo Ramil
Guillermo Ramil
EBElena Bussaglia
Elena Bussaglia
HCHelena Castellet
Helena Castellet
GOGuadalupe Oñate
Guadalupe Oñate
AGAna Garrido
Ana Garrido
JNJosep F. Nomdedeu
Josep F. Nomdedeu
Background: Isocitrate dehydrogenase ( IDH ) mutations are recurrent in acute myeloid leukemia (AML) and represent promising targets for measurable residual disease (MRD) monitoring. However, clinically validated strategies for IDH ‐based MRD assessment remain lacking. Methods: We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single‐center cohort of patients with IDH ‐mutated AML treated with curative intent. Healthy controls were included to characterize low‐level background signals and identify a clinical threshold. Results: ddPCR showed robust analytical performance, with a limit of detection of 0.01% variant allele frequency (VAF) and strong concordance with NGS. Low‐level IDH mutation signals were frequently detected in healthy individuals and in patients in remission. We identified 0.2% VAF as a candidate threshold for clinically relevant IDH MRD. Using this cutoff, post‐treatment detectable IDH MRD was associated with a higher 2‐year cumulative incidence of relapse (63.6% vs. 20%; p = 0.019) and inferior overall survival (70.6% vs. 92.9%; p = 0.04). Among patients negative by multiparameter flow cytometry, ddPCR identified residual IDH‐ mutated clones in 56% of cases, who showed higher relapse rates than double‐negative patients (50% vs. 0%; p = 0.031). Conclusions: A 0.2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH ‐based MRD assessment in AML.